ClinicalTrials.gg
Active, not recruitingNCT05568823ANTaRESUpdated Nov 20, 2026

Biomarkers of ANTidepressant RESponse and Development Risk of Bipolar Disorder

An interventional study of Blood sampling in Depression, Bipolar, Major Depressive Disorder and Bipolar Disorder, sponsored by Assistance Publique Hopitaux De Marseille. Active, not recruiting at 1 site in France. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Assistance Publique Hopitaux De Marseille · Not applicable, Interventional, and Treatment

How we know

Updated Nov 20, 2026Now Active, not recruitingFirst site in France+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
244
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 104 studies in Bipolar Disorder with a site in France — 34 open to participants now, 38 under way, 1 of them phase 3. Bipolar Disorder · France.

Planned enrollment
30th of 79
244 · median 170
Started
2023
with 6 others
No phase
56 of 104
22 open now
Primary completion
2027-08
later than 22 of 37 live
Registered
76th of 104
by date
Lead sponsor
5 of 104
Assistance Publique Hopitaux De Marseille

Among the 104 studies in Bipolar Disorder with a site in France, this one is the 30th largest by planned enrollment of the 79 interventional ones that give a count, is one of 7 that started in 2023, is one of 56 with no phase, reaches primary completion later than 22 of the 37 other live ones, and was the 76th registered.

Bipolar Disorder

1,687 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

34 of the 104 studies in Bipolar Disorder with a site in France are open now. Recruiting first, the newest first:

29 more — sign in →

All 34 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 207 Bipolar Disorder studies recruiting now, 60 (29%) set no upper age limit and 134 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 104 studies in Bipolar Disorder with a site in France, or all of them as a file.
02

Study summary

One in five people will present a major depressive episode (MDE) in their lifetime. While antidepressants (ADs) are currently the standard treatment for MDE, the first AD prescribed is effective in less than 40% of patients and a complete clinical response is only observed after several weeks. Identifying early biomarkers of the response to treatment with an AD could allow the clinician to rapidly identify patients in whom treatment will not be effective and therefore modify patient care. We have recently shown that the messenger RNA (mRNA) of two proteins, ELK1 and GPR56, were present in different amounts in the blood cells of "responder" compared to those of "non-respondent" patients. In this context, our main objective will be to determine whether ELK1 and GPR56 mRNAs, are very early biomarkers of the response to AD, i.e., biomarkers whose variation precedes the clinical response by several weeks. Secondary objectives will be to identify early phase changes in neurophysiological measures, cognitive and behavioral tasks, as well as levels of blood coding and non-coding RNAs, serum cytokine, mitochondrial and metabolic markers, neuroimaging markers as biomarkers of differential treatment outcomes to antidepressant treatment.

Patients will be treated with SERTRALINE or FLUOXETINE or DULOXETINE or MAPROTILINE (in monotherapy) with or without adjunct benzodiazepine.

Patients are identified as responders or non-responders based on their clinical assessment at 8 weeks after treatment onset.

In addition, a second stage will collect data to address another important issue for the management of patients with a MDE: to discriminate those with a major depressive disorder (MDD) from those with a bipolar disorder (BD). BD diagnosis is one of the most common reasons of failure to response to ADs. Therefore, one of our secondary objectives will be to identify biomarkers to differentiate between these two categories of patients. To do this, we will follow patients for a period of 24 months to identify those who will present during this follow-up the diagnostic criteria of bipolarity.

03

Conditions studied

  • Depression, Bipolar
  • Major Depressive Disorder
  • Bipolar Disorder
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patient between 18 and 65 years of age
  • Sufficient knowledge of the French language to complete the assessments
  • Inpatients or outpatients with a major depressive episode ( criteria);
  • Score above 19 on the MADRS depression scale (moderate to severe depression);
  • Without antidepressants, mood stabilizers or antipsychotics treatment or having stopped the previous medication(s) for more than 5 times the half-life of the prescribed treatment(s);
  • Eligible for antidepressant monotherapy with SERTRALINE or FLUOXETINE or DULOXETINE or MAPROTILINE, with or without benzodiazepine therapy, and in whom treatment is feasible within days of inclusion.

Exclusion criteria

Exclusion Criteria:

    • Patient with bipolar disorder, schizophrenia or psychotic disorder as defined by the and assessed by the MINI or any other pathology or treatment deemed clinically incompatible with the study by the investigator;

      • Patient with moderate to severe substance use disorders (>=4/11 criteria as defined in the DSM-5) and with the exception of smoking disorders
      • Patient with pregnancy, unstable physiological condition or severe and symptomatic medical condition;
      • Patient with a diagnosed neurological disorder affecting central nervous system function;
      • Patient unable to give to participate in this study or unable to give the volunteer informed information;
      • Patient who are not covered by a social security system;
      • Patient under court protection or guardianship
      • Patient who have received a vaccination within one month prior to initiation of treatment or who plan to be vaccinated within 2 weeks of initiation of treatment > For patient undergoing MRI: presence of a for MRI examination.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
244 participants (estimated)

Study arms

  • Other
    Patients "responding" to treatment after 8 weeks of treatment

    Patients "responding" to treatment after 8 weeks of treatment: i.e. whose clinical evolution is beneficial.

    Other: Blood sampling

  • Other
    Patients "non-responding" to treatment after 8 weeks of treatment

    Patients "non-responding" to treatment after 8 weeks of treatment: i.e. whose clinical evolution is not satisfactory.

    Other: Blood sampling

Interventions

  • OtherBlood sampling

    Measurement of markers of disease evolution

    Also known as: Psychiatric survey, MRI Exam

06

What researchers measure

Primary outcomes

  1. Predictive value for antidepressant response of ELK1 mRNA levels or changes 3 days after AD start

    The area under the curve (AUC) value determined by receiving operating characteristic (ROC) analysis of ELK1 mRNA levels for the evolution of psychiatric symptoms following AD start, during a 8-weeks follow-up. Patients are identified as responders or nonresponders based on their clinical assessment

    Time frame: 8 weeks of treatment

Secondary outcomes

  1. Predictive value for antidepressant response of GPR56 and ELK1 mRNA levels at baseline, 3 days, 2 weeks or 8 weeks after AD start

    The area under the curve (AUC) value determined by receiving operating characteristic (ROC) analysis of GPR56 and ELK1 ELISA tests from whole blood for the evolution of psychiatric symptoms following AD start, during a 8-weeks follow-up. Patients are identified as responders or nonresponders based on their clinical assessment

    Time frame: 8 weeks of treatment

  2. Predictive value for antidepressant response of coding and non-coding (micro, circular, long non coding) RNA blood levels at baseline, 3 days, 2 weeks or 8 weeks after AD start

    The area under the curve (AUC) value determined by receiving operating characteristic (ROC) analysis of coding and non-coding (micro, circular, long non coding) blood RNA levels for the evolution of psychiatric symptoms following AD start, during a 8-weeks follow-up. Patients are identified as responders or nonresponders based on their clinical assessment

    Time frame: 8 weeks of treatment

  3. Predictive value for antidepressant response of serum cytokine concentration measured by immunoassay at baseline, 3 days, 2 weeks or 8 weeks, after AD start

    The area under the curve (AUC) value determined by receiving operating characteristic (ROC) analysis of serum cytokine concentration measured by immunoassay for the evolution of psychiatric symptoms following AD start, during a 8-weeks follow-up. Patients are identified as responders or nonresponders based on their clinical assessment

    Time frame: 8 weeks of treatment

  4. Predictive value for antidepressant response of peripheral mitochondrial markers at baseline, 3 days 2 weeks or 8 weeks, after AD start Time Frame: 8 weeks of treatment

    The area under the curve (AUC) value determined by receiving operating characteristic (ROC) analysis of peripheral mitochondrial markers for the evolution of psychiatric symptoms following AD start, during a 8-weeks follow-up. Patients are identified as responders or nonresponders based on their clinical assessment

    Time frame: 8 weeks of treatment

  5. Predictive value for antidepressant response of MRI features

    The area under the curve (AUC) value determined by receiving operating characteristic (ROC) analysis of MRI analysis for the evolution of psychiatric symptoms following AD start, during a 8-weeks follow-up. Patients are identified as responders or nonresponders based on their clinical assessment

    Time frame: 8 weeks of treatment

07

Study locations

1 site
  • Hopital de Sainte Marguerite
    Marseille, France
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for Aug 2027, 54 months after the start.

Of 361 non-industry interventional studies with no phase under Bipolar Disorder, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 58. This study's planned 54 months is above that.

Counting every sponsor, half of 363 studies reached it within 37 months; a quarter within 23 and three quarters within 58.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 20, 2026: start Nov 2022 → Jan 2023, primary completion Nov 2024 → Aug 2027 and completion Jan 2025 → Aug 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 3, 2022
First posted
Oct 6, 2022
StartActual
Jan 30, 2023was Nov 2022
Primary completionEst.
Aug 13, 2027was Nov 2024
CompletionEst.
Aug 13, 2027was Jan 2025
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Active, not recruiting
changed Nov 20, 2026
Sites
1 site added — first site in France
Show site
  • Hopital de Sainte Marguerite · Marseille, France
Nov 20, 2026
Start date
Nov 1, 2022→Jan 30, 2023 (actual)
Nov 20, 2026
Primary completion
Nov 1, 2024→Aug 13, 2027
Nov 20, 2026
Study completion
Jan 2, 2025→Aug 13, 2027
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Status unknown→Active, not recruiting
    1 site added — first site in France
    Show site
    • Hopital de Sainte Marguerite · Marseille, France
    Start date Nov 1, 2022→Jan 30, 2023 (now actual)
    Primary completion Nov 1, 2024→Aug 13, 2027
    Study completion Jan 2, 2025→Aug 13, 2027
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05568823
Responsible party
Sponsor
First posted
Oct 6, 2022
Start date
Jan 30, 2023
Primary completion
Aug 13, 2027 (estimated)
Completion
Aug 13, 2027 (estimated)
Last update
Nov 20, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion